Epidemiologic studies of beta agonists and asthma deaths

Epidemiologic Reviews

Volumn 20, Issue 2, 1998, Pages 173-186

  Pearce, Neil ^a   Hensley, Michael J ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL; ISOPRENALINE; ORCIPRENALINE; SALBUTAMOL; TERBUTALINE;

ASTHMA; CASE CONTROL STUDY; COHORT ANALYSIS; METERED DOSE INHALER; MORTALITY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SELF CARE;

EID: 0032412469     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017979     Document Type: Review

References (75)

1. Beasley R, Pearce N, Crane J, et al. Asthma mortality and inhaled beta agonist therapy. Aust NZJ Med 1991;21: 753-63.
2. Beasley R, Pearce N, Crane J. The epidemiology of asthma mortality. In: O'Connor B, Giembycz M, eds. Clinical pharmacology of asthma. Basel, Switzerland: Birkhauser Verlag (in press).
3. Pearce N, Crane J, Burgess C, et al. Beta agonists and asthma mortality: déjà vu. Clin Exp Allergy 1991;21:401-10.
4. Speizer FE, Doll R. A century of asthma deaths in young people. Br Med J 1968;3:245-6.
5. Beasley R, Smith K, Pearce N, et al. Trends in asthma mortality in New Zealand, 1908-1986. Med J Aust 1990;152:570, 572-3.
6. Bauman A, Lee S. Trends in asthma mortality in Australia, 1911-1986. (Letter). Med J Aust 1990;153:366-7.
7. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. Br Med J 1968;1:335-9.
8. Inman WH, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969;2:279-85.
9. Asthma deaths: a question answered. (Editorial). Br Med J 1972;4:443-4.
10. 2-agonist controversy: observations, explanations and relationship to asthma epidemiology. Drug Safety 1994;11:259-83.
11. Taylor DR, Sears M. Regular beta-adrenergic agonists: evidence, not reassurance, is what is needed. Chest 1994;106: 552-9.
12. Van Metre TE Jr. Adverse effects of inhalation of excessive amounts of nebulized isoproterenol in status asthmaticus. J Allergy 1969;43:101-13.
13. Collins JM, McDevitt DG, Shanks RG, et al. The cardiotoxicity of isoprenaline during hypoxia. BrJ Pharmacol 1969; 36:35-45.
14. Stolley PD. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972;105:883-90.
15. Gandevia B. Pressurized sympathomimetic aerosols and their lack of relationship to asthma mortality in Australia. Med J Aust 1973;1:273-7.
16. Campbell AH. Mortality from asthma and bronchodilator aerosols. Med J Aust 1976;1:386-91.
17. Esdaile JM, Feinstein AR, Horwitz RI. A reappraisal of the United Kingdom epidemic of fatal asthma. Can general mortality data implicate a therapeutic agent? Arch Intern Med 1987;147:543-9.
18. Lanes SF, Walker AM. Do pressurized bronchodilator aerosols cause death among asthmatics? Am J Epidemiol 1987; 125:755-60.
19. Pearce N, Beasley R, Burgess C, et al. Asthma epidemiology: principles and methods. New York, NY: Oxford University Press, 1998.
20. Venning GR. Identification of adverse reactions to new drugs. I. What have been the important adverse reactions since thalidomide? Br Med J (Clin Res Ed) 1983;286:199-202.
21. Benatar SR. Fatal asthma. N Engl J Med 1986;314:423-9.
22. Paterson JW, Musk AW. Death in patients with asthma. (Editorial). Med J Aust 1987;147:53-5.
23. Buist AS. Is asthma mortality increasing? (Editorial). Chest 1988;93:449-50.
24. Read J. The reported increase in mortality from asthma: a clinico-functional analysis. Med J Aust 1968;1:879-84.
25. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 1978;7: 519-38.
26. Stolley PD, Lasky T. The bellman always rings thrice. (Letter). Ann Intern Med 1993;118:158.
27. Jackson RT, Beaglehole R, Rea HH, et al. Mortality from asthma: a new epidemic in New Zealand. Br Med J (Clin Res Ed) 1982;285:771-4.
28. Pearce N, Beasley R, Crane J, et al. End of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-4.
29. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989;1:917-22.
30. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990;45:170-5.
31. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991;46:105-11.
32. Pearce N, Crane J. Epidemiological methods for studying the role of beta agonist therapy in asthma mortality. In: Beasley R, Pearce NE, eds. The role of beta receptor agonist therapy in asthma mortality. Boca Raton, FL: CRC Press, 1993:67-83.
33. Sears MR, Rea HH, Beaglehole R, et al. Asthma mortality in New Zealand: a two year national study. N Z Med J 1985;98: 271-5.
34. Cox B, Elwood JM. The effect on the stratum-specific odds ratios of nondifferential misclassification of a dichotomous covariate. Am J Epidemiol 1991;133:202-7.
35. Elwood JM. Review of studies relating prescribed fenoterol to deaths from asthma in New Zealand. In: Beasley R, Pearce NE, eds. The role of beta receptor agonist therapy in asthma mortality. Boca Raton, FL: CRC Press, 1993:85-123.
36. Sackett DL, Shannon HS, Browman GW. Fenoterol and fatal asthma. (Letter). Lancet 1990;335:45-6.
37. Hensley MJ. Fenoterol and death from asthma. (Letter). Med J Aust 1992;156:882.
38. O'Donnell TV, Rea HH, Holst P, et al. Fenoterol and fatal asthma. (Letter). Lancet 1989;1:1070-1.
39. Buist AS, Burney PGJ, Feinstein AR, et al. Fenoterol and fatal asthma. (Letter). Lancet 1989;1:1071.
40. Poole C, Lanes SF, Walker AM. Fenoterol and fatal asthma. (Letter). Lancet 1990;335:920.
41. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near fatal death from asthma. N Engl J Med 1992;326:501-6.
42. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med 1994;149:604-10.
43. Beasley R, Pearce N, Crane J. The use of near fatal asthma for investigating asthma deaths. (Editorial). Thorax 1993;48: 1093-4.
44. 2-agonists. In: Shinomiya K, ed. Current advances in pediatric allergy and clinical immunology. Selected proceedings from the 32nd Annual Meeting of the Japanese Society of Pediatric Allergy and Clinical Immunology. Tokyo, Japan: Churchill Livingstone, 1996:161-4.
45. Criée CP, Quast CH, Ludtke R, et al. Use of beta agonists and mortality in patients with stable COPD. (Abstract). Eur Respir J 1993;6(Suppl 17):426S.
46. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336: 1391-6.
47. Trembath PW, Greenacre JK, Anderson M, et al. Comparison of four weeks' treatment with fenoterol and terbutaline aerosols in adult asthmatics: a double-blind crossover study. J Allergy Clin Immunol 1979;63:395-400.
48. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994;343:1379-82.
49. Bremner P, Siebers R, Crane J, et al. Partial vs full beta-receptor agonism: a clinical study of inhaled albuterol and fenoterol. Chest 1996;109:957-62.
50. Beasley R, Burgess C, Pearce N, et al. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 1994;24:660-8.
51. Walker AM, Lanes SF. Misclassification of covariates. Stat Med 1991;10:1181-96.
52. Garrett JE, Lanes SF, Kolbe J, et al. Risk of severe life threatening asthma and β agonist type: an example of confounding by severity. Thorax 1996;51:1093-9.
53. Rea HH, Garrett JE, Lanes SF, et al. The association between asthma drugs and severe life-threatening attacks. Chest 1996; 110:1446-51.
54. Burgess C, Pearce NE, Thiruchelvam R, et al. Prescribed drug therapy and mean-fatal asthma attacks. Eur Respir J 1994;7: 498-503.
55. Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21:737-44.
56. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993;148: 75-9.
57. 2-agonists. Am J Epidemiol 1996;144:1161-9.
58. Hensley MJ. Fenoterol and death from asthma. (Letter). Med J Aust 1992;156:882.
59. Horwitz RI, Spitzer WO, Buist S, et al. Clinical complexity and epidemiologic uncertainty in case-control research: fenoterol and asthma management. Chest 1991;100:1586-91.
60. Bown W. Warning letter links asthma deaths to drugs. New Scientist 1991;131 (27 July):15.
61. Crane J, Pearce N, Burgess C, et al. Asthma and the β-agonist debate. Thorax 1995;50:S5-10.
62. Pearce N, Crane J, Burgess C, et al. Beta agonists and death from asthma. (Letter). N Engl J Med 1992;327:355-7.
63. Pearce N, Crane J, Burgess C, et al. Beta agonist use and death from asthma. (Letter). JAMA 1994;271:822-3.
64. Mullen M, Mullen B, Carey M. The association between β-agonist use and death from asthma: a meta-analytic integration of case-control studies. JAMA 1993;270:1842-5.
65. Miller DB, Strunk RC. Circumstances surrounding the deaths of children due to asthma: a case-control study. Am J Dis Child 1989;143:1294-9.
66. Strunk RC, Mrazek DA, Wolfson Fuhrmann GS, et al. Physiologic and psychological characteristics associated with deaths due to asthma in childhood: a case-controlled study. JAMA 1985;254:1193-8.
67. Suissa S. The case-time-control design. Epidemiology 1995; 6:248-53.
68. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology 1996; 7:231-9.
69. Suissa S, Blais L, Ernst P. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994; 7:1602-9.
70. Woodman K, Pearce N, Beasley R, et al. Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study. Clin Pharmacol Ther 1992;51:566-71.
71. Lofdahl CG, Svedmyr N. Beta-agonists - friends or foes? (Editorial). Eur Respir J 1991;4:1161-5.
72. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet 1981;1:1235-7.
73. Sears MR, Rea HH, Fenwick J, et al. 75 deaths in asthmatics prescribed home nebulisers. Br Med J (Clin Res Ed) 1987; 294:477-80.
74. Keating G, Mitchell EA, Jackson R, et al. Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975-81. Br Med J (Clin Res Ed) 1984;289: 348-51.
75. Beasley R, Pearce N, Crane J. International trends in asthma mortality. Ciba Found Symp 1997;206:140-56.